Bio-Techne Corporation

TECH · Healthcare

$72.46
+0.01% today

What a holder would want to know before buying TECH: where the price sits in its own history, how far it has fallen before and whether it recovered, and what the business behind it earns. All of it is arithmetic over free market data — no opinions, no recommendations.

Where the price sits
Low $43.30 · May 2026High $72.61 · Sep 2026

Today’s price is 67% above the lowest point of the past year and 0% below the highest.

Over the past year it was cheaper than today on 95% of days and more expensive on 5%. Over the last 10 years: cheaper on 66% of days.

16% above its average price of the last 200 trading days.

How bad does it get

Fell 20% or more 3 times in 10 years. The deepest fall was 68%; the longest took 7 months to get back to its peak. 2 of 3 have recovered so far.

It is in one now: 46% below the Sep 2021 peak.

Sep 2021
−68%not back yet
Dec 2019
−27%back in 4 months
Sep 2018
−35%back in 7 months
What you own

Bio-Techne Corporation · Healthcare · Biotechnology · a large company worth $11.36B

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates…

Is it making money?
2023
2024
2025
2026

revenue profit

Sales of $1.22B in 2026, with $181.86M of profit. Sales grew in 2 of the last 3 years.

Keeps about 15 cents of every dollar of sales as profit.

Is it healthy?
Cash
$265.48M
Debt
$289.09M
Free cash flow / yr
$229.65M

Would need about 1.3 years of free cash flow to repay all its debt.

Is it expensive?

You pay $62 for every $1 of last year’s profit, and $31 for every $1 of profit expected next year.

A high number means buyers expect growth; a low one means they expect little, or fear trouble. Large US companies have averaged roughly 15–20 over the decades.

Pays 0.44% a year in dividends at today’s price · next ex-dividend Aug 24.

What others are doing

13 analysts: 1 say buy, 12 hold, 0 sell. Their average 12-month target is $70.50 (range $50.00–$73.00).

Insiders made 0 purchases and 1 sale in the last 6 months. Executives routinely sell shares they were paid in; buying with their own money is the rarer signal.

Free data from Yahoo Finance, refreshed daily. This is evidence about the business and its price history, not a recommendation.

Now try it without risking anything

Poshkan is paper trading: real prices, virtual money. Buy TECH with $10,000 that isn’t real, set a stop before you enter, and find out what your idea would actually have done.

Data from Yahoo Finance, refreshed hourly. Nothing here is financial advice. Poshkan is a paper-trading simulator — all money, trades and returns are virtual.